Related Experiment Videos

Antibody responses to four Haemophilus influenzae type b conjugate vaccines

H Käyhty1, J Eskola, H Peltola

  • 1Department of Bacteriology, National Public Health Institute, Helsinki, Finland.

Insights

This study compared Haemophilus influenzae type b conjugate vaccines in infants, adults, and children. PRP-T showed a better infant response after two doses, while all vaccines were equally effective in adults and children.

Area of Science:

  • Immunology
  • Vaccinology
  • Pediatrics

Background:

  • Haemophilus influenzae type b (Hib) poses a significant health risk, particularly to young children.
  • Conjugate vaccines are crucial for preventing Hib infections, but their immunogenicity can vary.
  • Understanding antibody responses to different Hib conjugate vaccines is vital for public health strategies.

Purpose of the Study:

  • To compare the serum antibody responses to four Haemophilus influenzae type b capsular polysaccharide-protein conjugate vaccines (PRP-D, HbOC, C7p, and PRP-T).
  • To evaluate vaccine efficacy across different age groups: infants, adults, and 2-year-old children.

Main Methods:

  • Serum antibody concentrations were measured using a Farr-type radioimmunoassay.
  • Infants received two vaccine doses at 4 and 6 months; adults and children received one dose.
  • Four conjugate vaccines were tested: PRP-D, HbOC, C7p, and PRP-T.

Main Results:

  • Infants showed a higher response to PRP-T after two doses compared to PRP-D, HbOC, and C7p.
  • PRP-D demonstrated a significantly lower geometric mean antibody concentration in infants post-vaccination.
  • Adults and 2-year-old children exhibited high and comparable antibody responses to all tested Hib conjugate vaccines after a single dose.

Conclusions:

  • PRP-T appears to be more immunogenic in infants after a two-dose regimen.
  • All tested Haemophilus influenzae type b conjugate vaccines are highly immunogenic in adults and young children with a single dose.
  • Vaccine selection may need to consider age-specific immunogenicity for optimal Hib prevention.

Related Concept Videos